<DOC>
	<DOCNO>NCT01017302</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate safety , tolerability , pharmacokinetics pharmacodynamics RO5095932 adult patient type 2 diabetes mellitus . Patients stable metformin therapy eligible enter study . There 5-weeks exenatide run period 5-weeks period co-administered study drug . RO5095932 administer subcutaneously single dose escalate dos . Patients randomize receive either active drug placebo week 1 4 . Active drug placebo administer weekly 4 week . Patients receive active drug week 1 4 receive placebo week 5 . Patients receive single dose placebo week 1 4 , receive single dose active drug week 5 . The anticipated time study treatment &lt; 6 month . The target sample size &lt; 100 patient .</brief_summary>
	<brief_title>A Study With RO5095932 Patients With Type 2 Diabetes Stable Metformin Therapy .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Adult patient , 1865 year age Diabetes mellitus , type 2 least 6 month screen On treatment stable dos metformin least 3 month screen BMI &gt; /=25 &lt; /=39 Type 1 diabetes Pancreatitis Treatment insulin one week within 3 month prior study start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>